Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

D. Malarikova, A. Berkova, A. Obr, P. Blahovcova, M. Svaton, K. Forsterova, E. Kriegova, E. Prihodova, L. Pavlistova, A. Petrackova, Z. Zemanova, M. Trneny, P. Klener,

. 2020 ; 12 (8) : . [pub] 20200731

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021897

Grantová podpora
AZV 17-28980A Ministerstvo Zdravotnictví Ceské Republiky
GA20-25308S Grantová Agentura České Republiky
UNCE/MED/016 Univerzita Karlova v Praze
PROGRES Q26/LF1 Ministerstvo Školství, Mládeže a Tělovýchovy
PROGRES Q28/LF1 Ministerstvo Školství, Mládeže a Tělovýchovy
RVO-VFN64165 Ministerstvo Zdravotnictví Ceské Republiky
DRO (FNOl, 00098892) Ministerstvo Zdravotnictví Ceské Republiky
IGA-LF-2019-001 Palacky University
NV17-28980A MZ0 CEP - Centrální evidence projektů

Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with a large number of recurrent cytogenetic/molecular aberrations. Approximately 5-10% of patients do not respond to frontline immunochemotherapy. Despite many useful prognostic indexes, a reliable marker of chemoresistance is not available. We evaluated the prognostic impact of seven recurrent gene aberrations including tumor suppressor protein P53 (TP53) and cyclin dependent kinase inhibitor 2A (CDKN2A) in the cohort of 126 newly diagnosed consecutive MCL patients with bone marrow involvement ≥5% using fluorescent in-situ hybridization (FISH) and next-generation sequencing (NGS). In contrast to TP53, no pathologic mutations of CDKN2A were detected by NGS. CDKN2A deletions were found exclusively in the context of other gene aberrations suggesting it represents a later event (after translocation t(11;14) and aberrations of TP53, or ataxia telangiectasia mutated (ATM)). Concurrent deletion of CDKN2A and aberration of TP53 (deletion and/or mutation) represented the most significant predictor of short EFS (median 3 months) and OS (median 10 months). Concurrent aberration of TP53 and CDKN2A is a new, simple, and relevant index of chemoresistance in MCL. Patients with concurrent aberration of TP53 and CDKN2A should be offered innovative anti-lymphoma therapy and upfront consolidation with allogeneic stem cell transplantation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021897
003      
CZ-PrNML
005      
20250521102234.0
007      
ta
008      
201125s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12082120 $2 doi
035    __
$a (PubMed)32751805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Maláriková, Diana $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic. Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic. $7 xx0332458
245    10
$a Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy / $c D. Malarikova, A. Berkova, A. Obr, P. Blahovcova, M. Svaton, K. Forsterova, E. Kriegova, E. Prihodova, L. Pavlistova, A. Petrackova, Z. Zemanova, M. Trneny, P. Klener,
520    9_
$a Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with a large number of recurrent cytogenetic/molecular aberrations. Approximately 5-10% of patients do not respond to frontline immunochemotherapy. Despite many useful prognostic indexes, a reliable marker of chemoresistance is not available. We evaluated the prognostic impact of seven recurrent gene aberrations including tumor suppressor protein P53 (TP53) and cyclin dependent kinase inhibitor 2A (CDKN2A) in the cohort of 126 newly diagnosed consecutive MCL patients with bone marrow involvement ≥5% using fluorescent in-situ hybridization (FISH) and next-generation sequencing (NGS). In contrast to TP53, no pathologic mutations of CDKN2A were detected by NGS. CDKN2A deletions were found exclusively in the context of other gene aberrations suggesting it represents a later event (after translocation t(11;14) and aberrations of TP53, or ataxia telangiectasia mutated (ATM)). Concurrent deletion of CDKN2A and aberration of TP53 (deletion and/or mutation) represented the most significant predictor of short EFS (median 3 months) and OS (median 10 months). Concurrent aberration of TP53 and CDKN2A is a new, simple, and relevant index of chemoresistance in MCL. Patients with concurrent aberration of TP53 and CDKN2A should be offered innovative anti-lymphoma therapy and upfront consolidation with allogeneic stem cell transplantation.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Berková, Adéla $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic. Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic. $7 xx0325890
700    1_
$a Obr, Ales $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic.
700    1_
$a Blahovcova, Petra $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
700    1_
$a Svaton, Michael $u CLIP, Department of Pediatric Hematology/Oncology, Second Faculty of Medicine and University Hospital in Motol, 15006 Prague, Czech Republic.
700    1_
$a Forsterova, Kristina $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
700    1_
$a Kriegova, Eva $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic.
700    1_
$a Prihodova, Eva $u Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
700    1_
$a Pavlistova, Lenka $u Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
700    1_
$a Petrackova, Anna $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic.
700    1_
$a Zemanova, Zuzana $u Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
700    1_
$a Trneny, Marek $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic.
700    1_
$a Klener, Pavel $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic. Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 8 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32751805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20250521102231 $b ABA008
999    __
$a ind $b bmc $g 1591606 $s 1112569
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 8 $e 20200731 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a AZV 17-28980A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a GA20-25308S $p Grantová Agentura České Republiky
GRA    __
$a UNCE/MED/016 $p Univerzita Karlova v Praze
GRA    __
$a PROGRES Q26/LF1 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a PROGRES Q28/LF1 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a RVO-VFN64165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a DRO (FNOl, 00098892) $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a IGA-LF-2019-001 $p Palacky University
GRA    __
$a NV17-28980A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace